An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Known clinically significant allergy to probenecid.
• •Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia.
• •Other active medical problems sufficient to hinder study compliance.
• •Concurrent Medication:
• •Excluded:
• •Amphotericin B.
• •Aminoglycoside antibiotics.
• •Vidarabine.
• •Intravenous pentamidine.
• •CMV hyperimmune immunoglobulin.
• •Other nephrotoxic or potentially nephrotoxic agents.
• •Other investigational agents with anti-CMV activity.
• •Ganciclovir.
• •Intravenous or oral acyclovir (except following development of herpetic lesion).
• •Foscarnet.
• •Diuretics.
• •Prior Medication:
• •Excluded within 2 days prior to study entry:
• •Ganciclovir or foscarnet.
• •Excluded within one week prior to study entry:
• •Amphotericin B.
• •Aminoglycoside antibiotics.
• •Vidarabine.
• •Intravenous pentamidine.
• •CMV hyperimmune immunoglobulin.
• •Other nephrotoxic agents.
• •Other investigational agents with anti-CMV activity.
• •Excluded at any time:
• •Prior systemic or intravitreal HPMPC.
• •Drug or alcohol abuse that is considered sufficient to hinder study compliance.